AbbVie Announces FDA Approval Of JUVMO For Parkinson's Disease

(RTTNews) - AbbVie (ABBV) announced the FDA has approved JUVMO tablets as the first and only selective D1/D5 receptor agonist for the treatment of adults with Parkinson's disease. The approval is supported by the Phase 3 TEMPO program. AbbVie expects to make JUVMO available to pa